Author Correction:Mesenchymal stromal cells in hepatic fibrosis/cirrhosis:from pathogenesis to treatment
作者机构：Department of Tumor Immunology and Gene Therapy Center Third Affiliated Hospital of Naval Medical University Shanghai 200438 China Key Laboratory on Signaling Regulation and Targeting Therapy of Liver Cancer Ministry of Education Eastern Hepatobiliary Surgery Hospital/National Center for Liver Cancer Naval Medical University Shanghai 200438 China The Third Affiliated Hospital of Soochow University Institutes for Translational Medicine State Key Laboratory of Radiation Medicine and Protection Key Laboratory of Stem Cells and Medical Biomaterials of Jiangsu Province Medical College of Soochow University Soochow University Suzhou 215000 China Department of Experimental Medicine TOR University of Rome Tor Vergata 00133 Rome Italy CAS Key Laboratory of Tissue Microenvironment and Tumor Shanghai Institute of Nutrition and Health University of Chinese Academy of Sciences Chinese Academy of Sciences Shanghai 200031 China
出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)
年 卷 期：2023年第20卷第6期
页 面：687-688页
核心收录：
学科分类：1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学]
基 金：supported by the National Key R&D Program of China 国家自然科学基金
主 题：Mesenchymal stromal cells Hepatic fibrosis/cirrhosis Pathogenesis Treatment Clinical application
摘 要：Hepatic fibrosis/cirrhosis is a significant health burden worldwide, resulting in liver failure or hepatocellular carcinoma (HCC) and accounting for many deaths each year. The pathogenesis of hepatic fibrosis/cirrhosis is very complex, which makes treatment challenging. Endogenous mesenchymal stromal cells (MSCs) have been shown to play pivotal roles in the pathogenesis of hepatic fibrosis. Paradoxically, exogenous MSCs have also been used in clinical trials for liver cirrhosis, and their effectiveness has been observed in most completed clinical trials. There are still many issues to be resolved to promote the use of MSCs in the clinic in the future. In this review, we will examine the controversial role of MSCs in the pathogenesis and treatment of hepatic fibrosis/cirrhosis. We also investigated the clinical trials involving MSCs in liver cirrhosis, summarized the parameters that need to be standardized, and discussed how to promote the use of MSCs from a clinical perspective.
维普期刊数据库